EconomyMarkets

Shares in COVID-19 vaccine developer Valneva extend fall By Reuters

© Reuters. FILE PHOTO: The logo of French-Austrian biotech firm Valneva is seen outside their headquarters in Vienna, Austria, December 16, 2021. REUTERS/Lisi Niesner

PARIS (Reuters) – Shares in biotech company Valneva fell again on Wednesday, declining for the seventh day in a row due to a growing belief amongst investors that the COVID-19 Omicron variant might lessen the need for mass vaccination.

At 0945 GMT, Valneva shares were down 3% at 17.10 euros, meaning the stock has now lost close to 40% since its Dec. 27 close of 26.38 euros.

It did gain more than 200% a year in 2021 and 2020 as Valneva’s COVID-19 vaccine candidate came increasingly closer to approval. It is still awaiting a green light for its shot in the European Union and Britain.

“The decline of the share price seems to be mostly driven by retail investors who think that there will be no need of a new vaccination campaign after the Omicron wave”, a Paris-based analyst said.

Companies whose COVID-19 vaccines have already been approved have also seen their shares dip since the start of the year, with Pfizer (NYSE:) losing 7.65% over the last two days and Moderna (NASDAQ:) down 8.2%.

Initial data in various countries seem to suggest that Omicron — the most contagious of all the COVID variants to date with new cases at record levels in many countries — is less likely to send infected people to hospital.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.


Source link

Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button